Pharmacokinetics and Pharmacodynamics of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects

Journal of Clinical Pharmacology

Volumn 49, Issue 10, 2009, Pages 1168-1175

  Sidharta, Patricia N ^a   Van Giersbergen, Paul L M ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Entry into humans study; Palosuran; Pharmacodynamics; Pharmacokinetics; Urotensin II; Urotensin II receptor antagonist

Indexed keywords

ACT 058362; CREATININE; PALOSURAN; POTASSIUM; RECEPTOR BLOCKING AGENT; SODIUM; UNCLASSIFIED DRUG; UROTENSIN II RECEPTOR ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEMATOMA; HUMAN; MALE; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PALLOR; POTASSIUM EXCRETION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM EXCRETION; SWEATING; VOMITING;

ADULT; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; POTASSIUM; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; SODIUM; TIME FACTORS; UREA; UROTENSINS;

EID: 70349515824     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009341181     Document Type: Article

References (39)

1. Bern HA, Lederis K. A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol. 1969 ; 45 (1 suppl). xi - xii.
2. Marshall WS, Bern HA Teleostean urophysis: urotensin II and ion transport across the isolated skin of a marine teleost. Science. 1979 ; 204 (4392). 519-521.
3. Thanassoulis G., Huyhn T., Giaid A. Urotensin II and cardiovascular diseases. Peptides. 2004 ; 25 (10). 1789-1794.
4. Watson AM, May CN Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides. 2004 ; 25 (10). 1759-1766.
5. Maguire JJ, Davenport AP Is urotensin-II the new endothelin ? Br J Pharmacol. 2002 ; 137 (5). 579-588.
6. Onan D., Hannan RD, Thomas WG Urotensin II: the old kid in town. Trends Endocrinol Metab. 2004 ; 15 (4). 175-182.
7. Lavecchia A., Cosconati S., Novellino E. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. J Med Chem. 2005 ; 48 (7). 2480-2492.
8. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999 ; 401 (6750). 282-286.
9. Douglas SA, Ohlstein EH Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med. 2000 ; 10 (6). 229-237.
10. Douglas SA Human urotensin-II as a novel cardiovascular target: heart of the matter or simply a fishy tail ? Curr Opin Pharmacol. 2003 ; 3 (2). 159-167.
11. Ong KL, Lam KS, Cheung BM Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther. 2005 ; 19 (1). 65-75.
12. Douglas SA, Dhanak D., Johns DG From gills to pills: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci. 2004 ; 25 (2). 76-85.
13. Affolter J., Webb DJ Urotensin II: a new mediator in cardiopulmonary regulation ? Lancet. 2001 ; 358 (9284). 774-775.
14. Maguire JJ, Kuc RE, Davenport AP Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol. 2000 ; 131 (3). 441-446.
15. Shenouda A., Douglas SA, Ohlstein EH, Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem. 2002 ; 50 (7). 885-889.
16. Douglas SA, Sulpizio AC, Piercy V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000 ; 131 (7). 1262-1274.
17. Camarda V., Rizzi A., Calo G., et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol. 2002 ; 365 (2). 141-149.
18. Cheung BM, Leung R., Man YB, Wong LY Plasma concentration of urotensin II is raised in hypertension. J Hypertens. 2004 ; 22 (7). 1341-1344.
19. Douglas SA, Tayara L., Ohlstein EH, Halawa N., Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002 ; 359 (9322). 1990-1997.
20. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides. 2004 ; 25 (10). 1767-1774.
21. Langham RG, Kelly DJ, Gow RM, et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis. 2004 ; 44 (5). 826-831.
22. Richards AM, Nicholls MG, Lainchbury JG, Fisher S., Yandle TG Plasma urotensin II in heart failure. Lancet. 2002 ; 360 (9332). 545-546.
23. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond). 2003 ; 104 (1). 1-5.
24. Totsune K., Takahashi K., Arihara Z., et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides. 2004 ; 25 (10). 1809-1814.
25. Heller J., Schepke M., Neef M., Woitas R., Rabe C., Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol. 2002 ; 37 (6). 767-772.
26. Clozel M., Binkert C., Birker-Robaczewska M., et al. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methylquinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther. 2004 ; 311 (1). 204-212.
27. Clozel M., Hess P., Qiu C., Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther. 2006 ; 316 (3). 1115-1121.
28. Bartels H., Bohmer M., Heierli C. Serum creatinine determination without protein precipitation. Clin Chim Acta. 1972 ; 37: 193-197.
29. Gough KHM, Keene O., Byrom B., Ellis S., Lacey L., McKellar J. Assessment of dose proportionality: report from the statisticians in The Pharmaceutical Industry/Pharmacokinetics UK joint working party. Drug Inf J. 1995 ; 29: 1039-1048.
30. Doggrell SA Urotensin-II and the cardiovascular system-the importance of developing modulators. Expert Opin Investig Drugs. 2004 ; 13 (5). 479-487.
31. Richards AM, Charles C. Urotensin II in the cardiovascular system. Peptides. 2004 ; 25 (10). 1795-1802.
32. Wilkinson IB, Affolter JT, de Haas SL, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res. 2002 ; 53 (2). 341-347.
33. Bhm F., Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol. 2002 ; 135 (1). 25-27.
34. Lu Y., Zou CJ, Huang DW, Tang CS Cardiovascular effects of urotensin II in different brain areas. Peptides. 2002 ; 23 (9). 1631-1635.
35. Watson AM, Lambert GW, Smith KJ, May CN. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension. 2003 ; 42 (3). 373-379.
36. Russell FD, Molenaar P. Cardiovascular actions of human urotensin II-considerations for hypertension. Naunyn Schmiedebergs Arch Pharmacol. 2004 ; 369 (3). 271-273.
37. Russell FD Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther. 2004 ; 103 (3). 223-243.
38. Winter MJ, Ashworth A., Bond H., Brierley MJ, McCrohan CR, Balment RJ The caudal neurosecretory system: control and function of a novel neuroendocrine system in fish. Biochem Cell Biol. 2000 ; 78 (3). 193-203.
39. Sidharta PN, Rave K., Heise T., Chiossi E., Dingemanse J. Effects of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with diabetes mellitus [abstract]. J Clin Pharmacol. 2006 ; 46: 1083.